RxDoctor Payments Data

John Bell, MD

Ophthalmology · Oklahoma City, OKNPI 1124094115

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 46 payments — averaging $33.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • The Cameron-ehlen Group, Inc.$302
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$291
  • Ellexiscience$181
  • Novartis$158
  • Bausch & Lomb Americas Inc.$135
  • Alcon$113
  • plus $358 from 10 others

What the payments were for

  • Food & beverage$1,51999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,537 in reported general payments places this provider in the 60th percentile of 183 ophthalmology providers in Oklahoma.

See all ophthalmology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$292,499
Medicare patients
919
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$28,039
Prednisolone Acetate406$17,381
Latanoprost885$9,708
LumiganBimatoprost13$8,015
Ofloxacin384$4,243
Timolol Maleate248$2,317
Cyclosporine11$2,262
ValacyclovirValacyclovir Hcl23$2,093
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat104$1,816
ErythromycinErythromycin Base128$1,391
Ketorolac Tromethamine41$782
Dorzolamide Hcl23$638
Brimonidine Tartrate55$481
Levobunolol Hcl17$309
Tobramycin15$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$36$36,05447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 183 ophthalmology providers in Oklahoma.

Other ophthalmology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →